Stock PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:50:43 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.1985 USD +1.07% Intraday chart for Provectus Biopharmaceuticals, Inc. +1.90% +106.77%
Apr. 18 Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose CI
Apr. 16 Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 19.23 24.72 23.43 23.07 45.43 40.27
Enterprise Value (EV) 1 33.11 44.5 47.13 24.13 47.59 43.22
P/E ratio -2.34 x -3.54 x -3.44 x -4.05 x -12.8 x -13 x
Yield - - - - - -
Capitalization / Revenue - - - - 45,934,892 x 72,213,378 x
EV / Revenue - - - - 48,121,944 x 77,502,175 x
EV / EBITDA -4.51 x -8.12 x -10 x -5.21 x -14.1 x -17.4 x
EV / FCF -9.47 x -11.7 x 44.5 x -3.48 x -39.6 x -37.2 x
FCF Yield -10.6% -8.52% 2.25% -28.8% -2.53% -2.68%
Price to Book -1.1 x -1.03 x -0.77 x -5.48 x -7.27 x -5.29 x
Nbr of stocks (in thousands) 384,615 389,889 401,232 419,447 419,497 419,522
Reference price 2 0.0500 0.0634 0.0584 0.0550 0.1083 0.0960
Announcement Date 3/7/19 3/5/20 3/2/21 3/29/22 3/30/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - 0.989 0.5577
EBITDA 1 -7.343 -5.48 -4.694 -4.628 -3.38 -2.489
EBIT 1 -8.028 -6.166 -4.936 -4.641 -3.391 -2.498
Operating Margin - - - - -342.86% -447.97%
Earnings before Tax (EBT) 1 -8.153 -6.923 -6.678 -5.54 -3.555 -3.102
Net income 1 -8.153 -6.923 -6.678 -5.54 -3.555 -3.102
Net margin - - - - -359.41% -556.16%
EPS 2 -0.0213 -0.0179 -0.0170 -0.0136 -0.008474 -0.007393
Free Cash Flow 1 -3.497 -3.793 1.059 -6.94 -1.202 -1.161
FCF margin - - - - -121.52% -208.09%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/7/19 3/5/20 3/2/21 3/29/22 3/30/23 3/28/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 13.9 19.8 23.7 1.06 2.16 2.95
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.89 x -3.61 x -5.049 x -0.2293 x -0.6399 x -1.185 x
Free Cash Flow 1 -3.5 -3.79 1.06 -6.94 -1.2 -1.16
ROE (net income / shareholders' equity) 59.4% 33.4% 24.6% 32.2% 68.3% 44.9%
ROA (Net income/ Total Assets) -185% -222% -299% -141% -76.4% -89.6%
Assets 1 4.407 3.112 2.236 3.918 4.655 3.462
Book Value Per Share 2 -0.0500 -0.0600 -0.0800 -0.0100 -0.0100 -0.0200
Cash Flow per Share 2 0 0 0 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/7/19 3/5/20 3/2/21 3/29/22 3/30/23 3/28/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PROVECTUS BIOPHARMACEUTICALS, INC. Stock Provectus Biopharmaceuticals, Inc.
+106.77% 83.28M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PVCT Stock
  4. Financials Provectus Biopharmaceuticals, Inc.